170 results
8-K
EX-99.1
ATHXQ
Athersys, Inc / New
11 Oct 23
Entry into a Material Definitive Agreement
9:27am
, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS … size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified
8-K
EX-99.1
ATHXQ
Athersys, Inc / New
3 Oct 23
Other Events
4:41pm
to establish safety and explore the potential for MAPC cells to reduce inflammation and promote healing which could provide meaningful benefits
424B4
ATHXQ
Athersys, Inc / New
21 Aug 23
Prospectus supplement with pricing info
2:36pm
and biologics, the product candidate is cleared from the body over time, which we believe may enhance product safety relative to other types of stem … and ARDS, if future clinical evaluation demonstrates appropriate safety and therapeutic effectiveness.
Business Strategy
Our principal business
8-K
EX-10.1
ATHXQ
Athersys, Inc / New
18 Aug 23
Placement Agency Agreement
10:14am
, occupational health and safety, product quality and safety and employment and labor matters, except in each case of (i), (ii) and (iii) as could not have
8-K
EX-10.1
2ozhtat405ug434 t9fw
18 Apr 23
Entry into a Material Definitive Agreement
8:26am
8-K
EX-10.1
yj1ra89i
10 Nov 22
Entry into a Material Definitive Agreement
2:04pm
424B5
9w1faylsj 0nl2svclp9
10 Nov 22
Prospectus supplement for primary offering
11:33am
424B5
3z8jgzzj th
7 Nov 22
Prospectus supplement for primary offering
4:06pm